Can-Fite BioPharma Ltd.

CANF | AMEX

Price Alert Chart Builder DCF Calculator

$2.22

-$0.02 (-0.89%)

At close: Sep 21, 2026, 4:00 PM ET

$2.26

+$0.04 (+1.74%)

Pre-market: Sep 22, 2026, 6:16 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $2.93M

Enterprise Value $-3.46M

Beta 0.02

Average Volume 1.55M

Shares Outstanding (Diluted) 11.37M

Shares Change YoY 87.33%

Institutional Ownership N/A

Exchange AMEX

ISIN US13471N4097

Price Performance

Price Change 1M -33.7%

Price Change 3M -27.2%

Price Change 6M -31.3%

Price Change YTD -49.5%

Price Change 1Y -82.4%

Price Change 3Y -95.6%

Price Change 5Y -99.3%

1M CAGR (ann.) -37.1%

1Y CAGR (ann.) -82.8%

5Y CAGR (ann.) -63.6%

All-Time CAGR -47.4%

Valuation

PE Ratio -2.47

Forward PE 2.75

PEG Ratio 0.00

Forward PEG 0.01

PS Ratio 5.19

Forward PS 1.00

PB Ratio 0.69

P/FCF Ratio -0.35

P/Adj. FCF Ratio -0.33

P/OCF Ratio -0.43

EV/Sales -6.18

EV/EBIT 0.39

EV/EBITDA 0.39

EV/FCF 0.41

Earnings Yield -40.5%

FCF Yield -287.5%

Adj. FCF Yield -301.9%

Financial Health

Net Cash $6.46M

Total Debt $90K

Cash & Short-Term Investments $6.46M

Total Assets $7.72M

Current Ratio 3.60

Quick Ratio 3.60

Debt / Equity Ratio 0.01

Debt / EBITDA -0.01

Debt / FCF -0.01

OCF / Debt -92.81

Interest Coverage 0.00

Altman Z-Score -33.40

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 100.0%

Operating Profit Margin -1595.4%

EBITDA Margin -2402.5%

Net Profit Margin -2358.8%

FCF Margin -1492.0%

Adj. FCF Margin -1567.0%

SBC / Revenue 44.7%

SBC Impact (per share) -5.0%

Returns

Return on Assets -118.6%

Return on Equity -182.9%

Return on Invested Capital -165.6%

Return on Capital Employed -166.9%

Return on Tangible Assets -118.6%

Historical Growth (CAGR)

Revenue CAGR 3Y -13.5%

Revenue CAGR 5Y -20.3%

Revenue CAGR 10Y 22.8%

EPS CAGR 3Y 61.3%

EPS CAGR 5Y 45.8%

EPS CAGR 10Y 31.7%

FCF CAGR 3Y -104.9%

FCF CAGR 5Y -86.5%

FCF CAGR 10Y -51.3%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 4

EPS Growth Next 3Y 47.8%

Revenue Growth Next 3Y 410.9%

Earnings Date N/A

EPS Estimate (next Q) N/A

EPS Growth Est (next Q) N/A

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $8

Price Target Upside 260.4%

Cash Flow

Operating Cash Flow $-8.35M

Free Cash Flow $-8.36M

Adj. Free Cash Flow $-8.78M

FCF Per Share -$5.13

OCF Per Share -$5.13

OCF/S Ratio -2348.4%

Income Statement

Revenue $560K

Gross Profit $560K

Operating Income $-8.93M

EBITDA $-8.91M

Net Income $-8.8M

EPS (Diluted) -$0.90

Revenue / Employee $112K

Profit / Employee $-1.76M

Employees 5